Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Nasdaq Jumps 270 Points; Silver Surges Over 8%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing around 270 points on Monday.
Looking Into LogicBio Therapeutics’s Recent Short Interest
LogicBio Therapeutics's (NASDAQ:LOGC) short percent of float has fallen 62.5% since its last report. The company recently reported that it has 29 thousand shares sold short, which is 0.12% of all regular shares that are available for trading.
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday’s Mid-Day Session
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Why LogicBio Therapeutics Stock Is Soaring Today
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher Monday after the company announced it will be acquired by AstraZeneca PLC (NASDAQ: AZN) subsidiary Alexion for $2.07 per share.
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
AstraZeneca Plc’s (NASDAQ:AZN) subsidiary, Alexion, has agreed to acquire LogicBio Therapeutics Inc (NASDAQ:LOGC) for $2.07 per share. Both boards have unanimously approved…
